Neurocrine BiosciencesLTS:0K6R +2.27%96 Median PS Value is $269.78 as of Jul. 03, 2026, which is 48075% above its 10-year median of 0.56. GuruFocus rates LTS:0K6R with a GF Score™ of 96/100 and a GF Value™ of $188.65 (Fairly Valued). The stock has 6 warning signs investors should review. Among 545 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 71.93% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Neurocrine Biosciences's Median PS Value or its related term are showing as below:
LTS:0K6R'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.41 Med: 0.56 Max: 8.41
Current: 0.64
During the past 13 years, the highest Price to Median PS Value of Neurocrine Biosciences was 8.41. The lowest was 0.41. And the median was 0.56.
LTS:0K6R's Price-to-Median-PS-Value is ranked better than 71.93% of 545
companies
in the Drug Manufacturers industry
Industry Median: 0.85
vs LTS:0K6R: 0.64
Neurocrine Biosciences (LTS:0K6R) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Neurocrine Biosciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
172.22
/
269.78
=
0.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Median PS Value Related Terms
Neurocrine Biosciences Median PS Value Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0K6R vs VTRS, ELAN, UTHR: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 8.9378.
Neurocrine Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.184.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (LTS:0K6R) has a Median PS Value of $269.78 as of Jul. 03, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Neurocrine Biosciences and its competitors. This is 48075% above median its historical median of 0.56. Over the past decade, Neurocrine Biosciences' Median PS Value has ranged from 0.41 to 8.41. According to the industry distribution chart, Neurocrine Biosciences ranks #153 out of 545 companies in the Drug Manufacturers industry, placing it in the top 28.1%.
Is Neurocrine Biosciences' Median PS Value too high?
Neurocrine Biosciences' current Median PS Value of $269.78 is 48075% above median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 8.41. The Drug Manufacturers industry median Median PS Value is 0.85. Neurocrine Biosciences' value of $269.78 is 31638.8% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #153 out of 545 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neurocrine Biosciences has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Median PS Value compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #153 out of 545 companies for Median PS Value. This puts Neurocrine Biosciences in the upper half of its industry. The industry median Median PS Value is 0.85. Neurocrine Biosciences' value of $269.78 is 31638.8% above this benchmark. Historically, Neurocrine Biosciences' own Median PS Value has ranged from 0.41 to 8.41 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 0.85, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.85, based on 545 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Median PS Value of $269.78 is 31638.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Median PS Value is $269.78, which is 48075% above median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Fairly Valued. The stock's GF Value™ is $188.65, compared to a current price of $172.22 — trading 8.7% below its estimated fair value. The current Median PS Value is $269.78, which is 48075% above median its 10-year median of 0.56 and 31638.8% above the Drug Manufacturers industry median of 0.85. Neurocrine Biosciences' overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current Median PS Value is $269.78 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of $172.22 is trading 8.7% below its estimated GF Value™ of $188.65.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for LTS:0K6R:
Median PS Value: $269.78 (48075% above median its 10-year median of 0.56)
GF Value™: $188.65 vs. price of $172.22 (8.7% below fair value)
Industry Position: 31638.8% above the Drug Manufacturers median (#153 of 545)
No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
96GF Score
Get the complete analysis for LTS:0K6R
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0K6R has been successfully added to your 
